1. Show article details.

    Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

    GlobeNewswire – 9:00 AM ET 06/07/2021

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO, and Sean Tucker, CSO, are scheduled to present at the SVB Leerink CybeRx Series: Vaccine Forum on Monday, June 21, 2021 at 1:00 p.m. Eastern Time.

  2. Show article details.

    Vaxart to Present at the Jefferies Virtual Healthcare Conference

    GlobeNewswire – 8:00 AM ET 05/27/2021

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu, CEO and Sean Tucker, CSO of the Vaxart (VXRT) executive team are scheduled to present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 p.m. Eastern Time.

  3. Show article details.

    BRIEF-Vaxart Announces First Subject Enrolled In Phase 1B Norovirus Dose-Ranging Trial In Elderly Adults

    Reuters – 8:08 AM ET 05/07/2021

    Vaxart Inc (VXRT): * VAXART ANNOUNCES FIRST SUBJECT ENROLLED IN PHASE 1B NOROVIRUS DOSE-RANGING TRIAL IN ELDERLY ADULTS. * Vaxart Inc (VXRT) - ALSO EXPECTS TO LAUNCH A PHASE 2 NOROVIRUS HUMAN CHALLENGE STUDY LATER THIS YEAR Source text for Eikon: Further company coverage:

  4. Show article details.

    Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

    GlobeNewswire – 8:00 AM ET 05/07/2021

    Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine. Safety and immunogenicity data to also inform oral COVID-19 vaccine program in older population.

  5. Show article details.

    Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

    GlobeNewswire – 8:00 AM ET 05/04/2021

    Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year. Study results may inform the COVID-19 oral vaccine program.

  6. Show article details.

    BRIEF-New Data From Vaxart Oral Covid-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity Against Other Coronaviruses

    Reuters – 6:02 PM ET 05/03/2021

    Vaxart Inc (VXRT): * NEW DATA FROM VAXART ORAL COVID-19 VACCINE PHASE I STUDY SUGGESTS BROAD CROSS-REACTIVITY AGAINST OTHER CORONAVIRUSES Source text for Eikon: Further company coverage:

  7. Show article details.

    New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

    GlobeNewswire – 5:06 PM ET 05/03/2021

    Vaxart (VXRT) oral vaccine induced higher CD8+ T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa, show broad cross-reactivity SOUTH SAN FRANCISCO, Calif., May 03, 2021 -- Vaxart (VXRT), Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rathe...

  8. Show article details.

    BRIEF-Vaxart Reports Q1 Loss Per Share Of $0.14

    Reuters – 8:33 AM ET 05/03/2021

    Vaxart Inc (VXRT): * VAXART REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.14. * Q1 REVENUE $506,000. * CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $177.3 MILLION AS OF MARCH 31, 2021 Source text for Eikon: Further company coverage:

  9. Show article details.

    Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

    GlobeNewswire – 8:00 AM ET 05/03/2021

    SOUTH SAN FRANCISCO, Calif., May 03, 2021 -- Vaxart (VXRT), Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by room-temperature stable tablet rather than by injection, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

  10. Show article details.

    Vaxart to Present at the World Vaccine Congress Washington 2021

    GlobeNewswire – 8:00 AM ET 04/29/2021

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the upcoming World Vaccine Congress Washington that will be held virtually from May 4-6, 2021.

  11. Show article details.

    Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines

    GlobeNewswire – 8:00 AM ET 04/26/2021

    Vaxart (VXRT) to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants.

  12. Show article details.

    BRIEF-Vaxart Appoints David Wheadon To Its Board Of Directors

    Reuters – 11:12 AM ET 04/23/2021

    Vaxart Inc (VXRT): * VAXART APPOINTS DAVID WHEADON, M.D., TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

  13. Show article details.

    Vaxart Appoints David Wheadon, M.D., to its Board of Directors

    GlobeNewswire – 8:00 AM ET 04/23/2021

    Vaxart (VXRT), Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon, M.D., to its Board of Directors. “We welcome Dr. Wheadon to our Board of Directors,” said Andrei Floroiu, chief executive officer of Vaxart.

  14. Show article details.

    Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans

    GlobeNewswire – 8:00 AM ET 04/22/2021

    Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds Seven in 10 said they would prefer a pill over an injection Nearly 19 million more American adults – about a third of those now refusing to get vaccinated – would get vaccinated if they could take a pill instead of getting a shot, according to a poll conducted by Quadrant S...

  15. Show article details.

    The Need for Comprehensive Diagnostics Remains as Cases Spike Once More

    PR Newswire – 9:00 AM ET 04/20/2021

    NEW YORK, April 20, 2021  The Director of the U.S. National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, and many other experts have warned that rapid reopening and lifting of pandemic restrictions in many states, as well as the proliferation of more contagious variants, will likely result in ongoing and increased spread of the virus in hot spots around the country.

  16. Show article details.

    Effective Diagnostics Help to Tame the Spread of the Pandemic

    PR Newswire – 9:00 AM ET 03/24/2021

    NEW YORK, March 24, 2021 Recent reports from across the country clearly show that infection cases are stabilizing. In the meantime, mass testing is crucial for governments to properly implement preventive measures throughout this pandemic.

  17. Show article details.

    Diagnostic Improvements Play a Key Role in the Abatement of the Pandemic

    PR Newswire – 9:00 AM ET 03/23/2021

    NEW YORK, March 23, 2021  Since the pandemic's inception and the subsequent pressure the healthcare infrastructure faced, effective mass testing has been necessary to come up with a proper plan to reduce case numbers. Now that vaccines are available and are being rolled out, the worries of the pandemic are slightly receding.

  18. Show article details.

    Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference

    GlobeNewswire – 4:01 PM ET 03/04/2021

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021.

  19. Show article details.

    Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

    GlobeNewswire – 4:01 PM ET 02/25/2021

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 -- Vaxart, Inc. (VXRT) a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it plans to initiate the first Phase 2 study of its oral COVID-19 vaccine candidate, VXA-CoV2-1, in 2Q 2021.

  20. Show article details.

    Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021

    GlobeNewswire – 4:01 PM ET 02/24/2021

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021.

Page:

Today's and Upcoming Events

  • Aug
    04

    VXRT to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    03

    VXRT announced Q1 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.